"
Team:Imperial College London/Manufacturing Considerations
From 2009.igem.org
(→Manufacturing Considerations) |
JamesField (Talk | contribs) (→Manufacturing Considerations) |
||
| Line 1: | Line 1: | ||
{{Imperial/09/TemplateTop}} | {{Imperial/09/TemplateTop}} | ||
| - | = | + | =Pill Manufacture= |
Pill manufacture is not only concerned with drug release but also by synthesis, purification, packaging, storage, administration and quality control. <i>The E.ncapsulator</i> has been designed to address each of these important manufacturing considerations. | Pill manufacture is not only concerned with drug release but also by synthesis, purification, packaging, storage, administration and quality control. <i>The E.ncapsulator</i> has been designed to address each of these important manufacturing considerations. | ||
Revision as of 17:02, 7 October 2009
Pill Manufacture
Pill manufacture is not only concerned with drug release but also by synthesis, purification, packaging, storage, administration and quality control. The E.ncapsulator has been designed to address each of these important manufacturing considerations.
If The E.ncapsulator is to be adopted as a drug delivery platform, it must be able to synthesise any polypeptide. To this end, we have designed a 'universal adaptor' such that peptides which do not begin with the amino acid methionine can be synthesised. In addition, we have 'codon optimised' all non native E.coli genes to maximise gene expression efficiency.
In The E.ncapsulator, polypeptide synthesis (Module 1) and packaging (Module 2) occur in the same place. This means that there is no need for expensive downstream purification protocols.
Storage has been considered in two ways. Firstly trehalose facilitates freeze drying and secondly we have been experimenting with a number if secondary encapsulation technologies including: xantham gum, milk protein and gelatin.
Edible and cheap secondary capsule. Primary capsule facilitates delivery past stomach.
Since we are depending on a population of cells to produce a biologically active polypeptide our bets are hedged. In that if one cell fails to produce any protein it will have a minimal impact on the whole system.
Another important aspect of quality control is safety. To minimise risks associated with our product, we have chosen a GRAS chassis. In addition, The E.ncapsulator's DNA is deleted prior to ingestion (Module 3). This will protect against the risks of horizontal gene transfer and colonisation.
